AEON Cuts Two-Year Warrant Strike to $0.20, Expects $6.2M From Exercises Before Nov 16 Expiry
AEON sits 58% above its 52-week low of $0.177.
Summary
AEON cut the exercise price on its Two-Year Milestone Warrants from $0.3221 to $0.20 and expects about $6.2 million in gross proceeds as holders exercise ahead of the November 16, 2026 expiration. Total potential warrant proceeds drop to roughly $24.4 million from $29.6 million.
Key Events · Financing and Capital Events · AEON
-
Warrant Strike Cut to $0.20
Effective November 2, 2026, the Two-Year Milestone Warrants' exercise price fell from $0.3221 to $0.20 per share, and from $0.3220 to $0.1999 per Pre-Funded Warrant. Holders representing at least 67% consented, and the change binds all outstanding Two-Year Warrants.
-
About $6.2M Expected From Exercises
Certain consenting holders agreed to exercise at the reduced price, and the company expects approximately $6.2 million in gross proceeds. Total potential proceeds from all Milestone Warrants fall to approximately $24.4 million from approximately $29.6 million.
-
November 16, 2026 Expiration Looms
The September 30, 2026 FDA Type 2b meeting minutes triggered accelerated expiration of the Two-Year Warrants, which expire November 16, 2026. The Five-Year Milestone Warrants were not amended.
-
Dilution Against 71.5M Shares
71,517,020 shares of Common Stock were outstanding as of October 30, 2026. The prospectus supplement covers 17,851,599 shares plus 110,214,222 shares underlying the Pre-Funded and Milestone Warrants.
Analysis · AEON · Life Sciences
AEON traded near-term dilution for near-term cash. Holders of at least 67% of the Two-Year Warrants agreed to drop the strike from $0.3221 to $0.20 — about 38% below the original — and some have already committed to exercise, which should bring in roughly $6.2 million of gross proceeds. The trade-off: the full warrant package now yields about $24.4 million instead of the roughly $29.6 million previously contemplated. The clock is the real driver. The warrants expire November 16, 2026, after the September 30 FDA Type 2b minutes triggered accelerated expiration, so a strike above the $0.273 last reported sale price on November 2 would likely have produced nothing. At $0.20 the warrants sit below that reference price, which is what makes exercise rational for holders. For a company this small, $6.2 million is meaningful runway, but it comes with real share issuance against 71,517,020 shares outstanding as of October 30, 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AEON was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.1M. The 52-week trading range was $0.18 to $1.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.